ClinicalTrials.gg
RecruitingNCT06107582Updated Feb 11, 2026

Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)

An observational study in Primary Immune Thrombocytopenia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Purpura, Thrombocytopenic, Idiopathic by Institute of Hematology & Blood Diseases Hospital, China — 27 open to participants now, 29 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Institute of Hematology & Blood Diseases Hospital, China.

Started
2023
with 5 others
Observational
2 of 33
2 open now
Primary completion
2026-12
later than 18 of 28 live
Registered
12th of 33
by date

Among the 33 studies in Purpura, Thrombocytopenic, Idiopathic by Institute of Hematology & Blood Diseases Hospital, China, this one is one of 6 that started in 2023, is one of 2 observational ones, reaches primary completion later than 18 of the 28 other live ones, and was the 12th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

27 of the 33 studies in Purpura, Thrombocytopenic, Idiopathic by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

Where they have run

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Purpura, Thrombocytopenic, Idiopathic by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

Immune thrombocytopenic purpura (ITP) is a kind of rare childhood disease that involve autoimmune destruction of platelets.The current Pediatric ITP cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in pediatric ITP. The purpose of this study is to analyze the clinical characteristics of Pediatric ITP, the treatment methods, prognosis and prognostic model of these patients in China.

Read the detailed description

Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease, which is characterized by decreased platelet count and skin and mucosal bleeding. ITP is a kind of disease with increased platelet destruction and impaired platelet production caused by autoimmunity. Conventional treatment of adult ITP includes first-line glucocorticoid and immunoglobulin therapy, second line TPO and TPO receptor agonist, splenectomy and other immunosuppressive treatments (such as rituximab, vincristine, azathioprine, etc.). ITP is one of the most common hemorrhagic diseases. At present, the treatment response of ITP is not good, and a considerable number of patients need drug maintenance treatment, which seriously affects the quality of life of patients and increases the economic burden of patients. Longitudinal Cohort allows to describe the long-term clinical characteristics of pediatric ITP patients, to study the benefit-risk balance of treatments, including the growing development of targeted therapies and to analyze the prognostic factors and attempts to establish prognostic models.

The study will include pediatric patients diagnosed with primary immune thrombocytopenia in the investigating hospitals, and collect basic information, diagnostic and treatment information from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.

03

Conditions studied

  • Primary Immune Thrombocytopenia
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Pediatric patients who were diagnosed with ITP in the investigating hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6-17 years old (including both ends), male and female;
  • Diagnosis of ITP.

Exclusion criteria

Exclusion Criteria:

  • Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, , drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.;
  • The expected follow-up period is less than 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pediatric Primary Immune Thrombocytopenia

    Immune thrombocytopenia (ITP) : defined according to the international working group criteria

    Other: data collection

Interventions

  • Otherdata collection

    The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Overall response rate defined as proportion of subjects with a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding

    Time frame: 3 years

  2. Time to onset response

    Time to onset response defined as the time needed for subjects to have a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding

    Time frame: 3 years

  3. Duration of response

    Duration of response defined as the longest duration for which the subject sustained a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding

    Time frame: 3 years

  4. Sustained response rate

    Sustained response rate defined as proportion of subjects who keep a platelet count ≥ 30 × 10\^9/L and at least 2-fold from baseline without bleeding at 6, 12, 24, 36 months after initial administration of certain treatment in absence of rescue therapy

    Time frame: 3 years

  5. Emergency treatment

    Percentage of subjects who received emergency treatment after initial administration of certain treatment

    Time frame: 3 years

  6. Number of subjects with clinically significant bleeding as assessed using the bleeding scale for pediatric patients with ITP after initial administration of certain treatment

    Changes of the subjects' numbers in bleeding score after administration of certain treatment according to the reported bleeding scale for pediatric patients with ITP. The bleeding scale for pediatric patients with ITP is a measure of bleeding severity with the following grades: Grade 1 (minor) Minor bleeding, few petechiae (≤100 total) and/or ≤5 small bruises (≤3 cm in diameter), no mucosal bleeding;Grade 2 (mild) Mild bleeding, many petechiae (\>100 total) and/or \>5 large bruises (\>3 cm in diameter), no mucosal bleeding;Grade 3 (moderate) Moderate bleeding, overt mucosal bleeding, troublesome lifestyle;Grade 4 (severe) Severe bleeding, mucosal bleeding leading to decrease in Hb\>2 g/dL or suspected internal hemorrhage;

    Time frame: 3 years

  7. Number of subjects with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale after initial administration of certain treatment

    Changes of the subjects' numbers in WHO bleeding score after administration of certain treatment according to the reported World Health Organization's Bleeding Scale. The WHO Bleeding Scale is a measure of bleeding severity with the following grades: grade 0 = no bleeding, grade 1= petechiae, grade 2= mild blood loss, grade 3 = gross blood loss, and grade 4 = debilitating blood loss.

    Time frame: 3 years

  8. Recurrence-free survival rate

    Time from the start of treatment to the occurrence of a relapse or death event

    Time frame: 3 years

Secondary outcomes

  1. Incidence

    The incidence of pediatric primary immune thrombocytopenia in China will be described

    Time frame: 3 years

  2. Distribution

    The population characteristics of pediatric primary immune thrombocytopenia in China will be described

    Time frame: 3 years

  3. Prognosis related factors selected from transcriptome data

    The prognosis related factors will be selected from transcriptome data and be used to establish prognosis prediction model

    Time frame: 3 years

  4. Prognosis related factors selected from proteomics data

    The prognosis related factors will be selected from proteomics data and be used to establish prognosis prediction model

    Time frame: 3 years

  5. Prognosis related factors selected from metabolomics data

    The prognosis related factors will be selected from metabolomics data and be used to establish prognosis prediction model

    Time frame: 3 years

  6. Prognosis related factors selected from microbiome data

    The prognosis related factors will be selected from proteomics data and be used to establish prognosis prediction model

    Time frame: 3 years

  7. Incidence, severity, and relationship of treatment emergent adverse events after treatment

    Incidence, severity, and relationship of treatment emergent adverse events after treatment will be analyzed

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 31 observational studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 35. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2023
First posted
Oct 30, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2036
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06107582
Collaborators
Beijing Children's Hospital, Tianjin People's Hospital, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University, The Second Affiliated Hospital of Kunming Medical University
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Nov 1, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2036 (estimated)
Last update
Feb 11, 2026

Study contacts

Ting Sun, MD
Contact
sunting@ihcams.ac.cn
02223909009
Lei Zhang, MD
principal investigator · Chinese Academy of Medical Science and Blood Disease Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion